CRB-913
CANYON-1
Corbus Pharmaceuticals · Phase 1 · Completed · Enrollment 254
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part 1: PK Lead-in | n/r | n/r | n/r | n/r |
| Part 2: CRB-913 low dose | n/r | n/r | n/r | n/r |
| Part 2: CRB-913 Medium Dose | n/r | n/r | n/r | n/r |
| Part 2: CRB-913 High Dose | n/r | n/r | n/r | n/r |
| Part 2: Placebo | n/r | n/r | n/r | n/r |
Not shown
- Part 1: PK Lead-in: endpoint not reported
- Part 2: CRB-913 low dose: endpoint not reported
- Part 2: CRB-913 Medium Dose: endpoint not reported
- Part 2: CRB-913 High Dose: endpoint not reported
- Part 2: Placebo: endpoint not reported